Published in J Clin Microbiol on January 01, 2002
Decrease in antibiotic use among children in the 1990s: not all antibiotics, not all children. CMAJ (2004) 1.06
In vitro activities of ABT-492, a new fluoroquinolone, against 155 aerobic and 171 anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis. Antimicrob Agents Chemother (2003) 0.94
Antibiotic-resistant invasive pediatric Streptococcus pneumoniae clones in Israel. J Clin Microbiol (2003) 0.87
Phenotypic and genotypic characterization of invasive Streptococcus pneumoniae clinical isolates. Curr Ther Res Clin Exp (2004) 0.78
Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol (1995) 88.05
Intercontinental spread of a multiresistant clone of serotype 23F Streptococcus pneumoniae. J Infect Dis (1991) 6.69
Nomenclature of major antimicrobial-resistant clones of Streptococcus pneumoniae defined by the pneumococcal molecular epidemiology network. J Clin Microbiol (2001) 6.66
Emergence of drug-resistant pneumococcal infections in the United States. JAMA (1994) 6.29
Horizontal transfer of multiple penicillin-binding protein genes, and capsular biosynthetic genes, in natural populations of Streptococcus pneumoniae. Mol Microbiol (1991) 5.45
Infections caused by Streptococcus pneumoniae: clinical spectrum, pathogenesis, immunity, and treatment. Clin Infect Dis (1992) 5.17
Cephalosporin treatment failure in penicillin- and cephalosporin-resistant Streptococcus pneumoniae meningitis. Pediatr Infect Dis J (1992) 3.84
The quellung reaction, a neglected microbiologic technique. Mt Sinai J Med (1977) 3.78
Random amplified polymorphic DNA typing of Pseudomonas aeruginosa isolates recovered from patients with cystic fibrosis. J Clin Microbiol (1996) 3.74
Analysis of multiply antimicrobial-resistant isolates of Streptococcus pneumoniae from the United States. Antimicrob Agents Chemother (1992) 3.39
Origin and molecular epidemiology of penicillin-binding-protein-mediated resistance to beta-lactam antibiotics. Trends Microbiol (1994) 2.99
Epidemiology of Burkholderia cepacia infection in patients with cystic fibrosis: analysis by randomly amplified polymorphic DNA fingerprinting. J Clin Microbiol (1996) 2.95
Comparative study of five different DNA fingerprint techniques for molecular typing of Streptococcus pneumoniae strains. J Clin Microbiol (1995) 2.55
Serogroup-specific epidemiology of Streptococcus pneumoniae: associations with age, sex, and geography in 7,000 episodes of invasive disease. Clin Infect Dis (1996) 2.29
Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. Pediatr Infect Dis J (1999) 1.84
Invasive Streptococcus pneumoniae infections: serotype distribution and antimicrobial resistance in Canada, 1992-1995. CMAJ (1998) 1.78
Canadian national survey of prevalence of antimicrobial resistance among clinical isolates of Streptococcus pneumoniae. Canadian Bacterial Surveillance Network. Antimicrob Agents Chemother (1996) 1.74
Molecular epidemiologic characterization of penicillin-resistant Streptococcus pneumoniae invasive pediatric isolates recovered in six Latin-American countries: an overview. PAHO/Rockefeller University Workshop. Pan American Health Organization. Microb Drug Resist (1998) 1.54
Antibiotic-resistant pneumococcal disease in South African children. Am J Dis Child (1992) 1.49
Surveillance of invasive Streptococcus pneumoniae infection in Quebec, Canada, from 1984 to 1986: serotype distribution, antimicrobial susceptibility, and clinical characteristics. J Clin Microbiol (1989) 1.48
Acquisition, carriage, and transmission of pneumococci with decreased antibiotic susceptibility in young children attending a day care facility in southern Israel. J Infect Dis (1998) 1.42
Invasive pneumococcal infections in Canadian children, 1991-1998: implications for new vaccination strategies. Canadian Paediatric Society/Laboratory Centre for Disease Control Immunization Monitoring Program, Active (IMPACT). Clin Infect Dis (2000) 1.36
High incidence of resistance to multiple antimicrobials in clinical isolates of Streptococcus pneumoniae from a university hospital in Korea. Clin Infect Dis (1995) 1.34
A global gene pool for high-level cephalosporin resistance in commensal Streptococcus species and Streptococcus pneumoniae. J Infect Dis (1997) 1.33
Streptococcus pneumoniae carriage in children attending 59 Canadian child care centers. Toronto Child Care Centre Study Group. Arch Pediatr Adolesc Med (1999) 1.30
The use of Streptococcus pneumoniae nasopharyngeal isolates from healthy children to predict features of invasive disease. Pediatr Infect Dis J (1998) 1.26
Defining the public health impact of drug-resistant Streptococcus pneumoniae: report of a working group. MMWR Recomm Rep (1996) 1.19
Application of molecular typing to the epidemiology of Streptococcus pneumoniae. J Clin Pathol (1998) 1.11
Molecular characterization of penicillin-resistant Streptococcus pneumoniae isolates from Bulgaria. J Clin Microbiol (1999) 1.04
Surveillance of invasive Streptococcus pneumoniae infection in the province of Quebec, Canada, from 1996 to 1998: serotype distribution, Antimicrobial susceptibility, and clinical characteristics. J Clin Microbiol (2001) 1.00
Antibiotic-resistant pneumococci in pediatric disease. Microb Drug Resist (1995) 0.96
Molecular tools for epidemiologic study of infectious diseases. Pediatr Infect Dis J (1998) 0.88
Benefit and risk in the beta-lactam antibiotic-resistance strategies of Streptococcus pneumoniae and Staphylococcus aureus. Trends Microbiol (1994) 0.86
Antibiotic treatment for acute otitis media. Int J Antimicrob Agents (2000) 0.81
Middle ear fluid concentrations of amoxicillin after large dosages in children with acute otitis media. Pediatr Infect Dis J (1998) 0.78
Epidemiology of penicillin resistance in Streptococcus pneumoniae isolates in eastern France. Clin Microbiol Infect (1998) 0.77
Identification of herpes simplex virus DNA sequences which encode a trans-acting polypeptide responsible for stimulation of immediate early transcription. J Mol Biol (1984) 8.87
Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme. JAMA (2000) 8.06
Pseudomonas aeruginosa isolates from patients with cystic fibrosis: a class of serum-sensitive, nontypable strains deficient in lipopolysaccharide O side chains. Infect Immun (1983) 6.24
A complex formed between cell components and an HSV structural polypeptide binds to a viral immediate early gene regulatory DNA sequence. Cell (1988) 4.68
Monitoring adverse reactions to new drugs: "restricted release" or "monitored release"? Br Med J (1977) 4.20
Nonmotility and phagocytic resistance of Pseudomonas aeruginosa isolates from chronically colonized patients with cystic fibrosis. Infect Immun (1994) 3.83
Diagnostically and experimentally useful panel of strains from the Burkholderia cepacia complex. J Clin Microbiol (2000) 3.77
Random amplified polymorphic DNA typing of Pseudomonas aeruginosa isolates recovered from patients with cystic fibrosis. J Clin Microbiol (1996) 3.74
"Black blood" T2-weighted inversion-recovery MR imaging of the heart. Radiology (1996) 3.34
Identification of Burkholderia cepacia isolates from patients with cystic fibrosis and use of a simple new selective medium. J Clin Microbiol (1997) 3.33
Rapid diagnosis of Hemophilus influenzae type b infections by latex particle agglutination and counterimmunoelectrophoresis. J Pediatr (1978) 3.05
Epidemiology of Burkholderia cepacia infection in patients with cystic fibrosis: analysis by randomly amplified polymorphic DNA fingerprinting. J Clin Microbiol (1996) 2.95
Functional analysis of a herpes simplex virus type 1 promoter: identification of far-upstream regulatory sequences. Nucleic Acids Res (1983) 2.78
Pattern of non-steroidal anti-inflammatory drug use in Australia 1990-1994. A report from the Drug Utilization Sub-Committee of the Pharmaceutical Benefits Advisory Committee. Med J Aust (1996) 2.78
Identification and characterization of a novel DNA marker associated with epidemic Burkholderia cepacia strains recovered from patients with cystic fibrosis. J Clin Microbiol (1997) 2.72
Identification and population structure of Burkholderia stabilis sp. nov. (formerly Burkholderia cepacia genomovar IV). J Clin Microbiol (2000) 2.63
The 65,000-Mr DNA-binding and virion trans-inducing proteins of herpes simplex virus type 1. J Virol (1987) 2.63
Greater toxicity in overdose of dothiepin than of other tricyclic antidepressants. Lancet (1994) 2.62
Disproportionate distribution of Burkholderia cepacia complex species and transmissibility markers in cystic fibrosis. Am J Respir Crit Care Med (2001) 2.55
Non-prescription use of bronchodilator aerosols. Med J Aust (1992) 2.41
Burkholderia cenocepacia in cystic fibrosis: epidemiology and molecular mechanisms of virulence. Clin Microbiol Infect (2010) 2.41
Burkholderia ambifaria sp. nov., a novel member of the Burkholderia cepacia complex including biocontrol and cystic fibrosis-related isolates. Int J Syst Evol Microbiol (2001) 2.27
Attitudes of physicians and public to pharmaceutical industry 'gifts'. Intern Med J (2010) 2.20
Giving and receiving of gifts between pharmaceutical companies and medical specialists in Australia. Intern Med J (2006) 2.19
Intravenous contrast media: use and associated mortality. Med J Aust (1991) 2.18
Xanthomonas maltophilia misidentified as Pseudomonas cepacia in cultures of sputum from patients with cystic fibrosis: a diagnostic pitfall with major clinical implications. Clin Infect Dis (1995) 2.15
Changes to the Pharmaceutical Benefits Advisory Committee. Med J Aust (2001) 2.14
Nonopsonic phagocytosis of strains of Pseudomonas aeruginosa from cystic fibrosis patients. Infect Immun (1984) 2.12
Cimetidine and ranitidine: comparison of effects on hepatic drug metabolism. Br Med J (1980) 2.09
Phenotypic methods for determining genomovar status of the Burkholderia cepacia complex. J Clin Microbiol (2001) 2.06
Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. Am J Respir Crit Care Med (2000) 2.04
Use of a pilin gene probe to study molecular epidemiology of Pseudomonas aeruginosa. J Clin Microbiol (1989) 2.04
Infection with Burkholderia cepacia complex genomovars in patients with cystic fibrosis: virulent transmissible strains of genomovar III can replace Burkholderia multivorans. Clin Infect Dis (2001) 2.04
Influenza immunization in children with chronic arthritis: a prospective study. J Rheumatol (1993) 1.92
Enhanced gene replacement in mycobacteria. Microbiology (1999) 1.91
Regulation of the inducible acetamidase gene of Mycobacterium smegmatis. Microbiology (1997) 1.86
Nonopsonic phagocytosis of nonmucoid Pseudomonas aeruginosa by human neutrophils and monocyte-derived macrophages is correlated with bacterial piliation and hydrophobicity. Infect Immun (1986) 1.80
Polysaccharide surface antigens expressed by nonmucoid isolates of Pseudomonas aeruginosa from cystic fibrosis patients. J Clin Microbiol (1986) 1.76
Hospital epidemiology of Pseudomonas aeruginosa from patients with cystic fibrosis. J Hosp Infect (1987) 1.74
Role of ornibactin biosynthesis in the virulence of Burkholderia cepacia: characterization of pvdA, the gene encoding L-ornithine N(5)-oxygenase. Infect Immun (1999) 1.70
Serial isolates of Pseudomonas aeruginosa from a cystic fibrosis patient have identical pilin sequences. Infect Immun (1988) 1.68
Adverse reactions to N-acetylcysteine during treatment for paracetamol poisoning. Med J Aust (1989) 1.68
Local adverse effects of meningococcal vaccine. CMAJ (1994) 1.66
Genetic adaptation of Pseudomonas aeruginosa to the airways of cystic fibrosis patients is catalyzed by hypermutation. J Bacteriol (2008) 1.63
Cimetidine and ranitidine in duodenal ulcer. Br Med J (1980) 1.63
Mucoid Pseudomonas aeruginosa resists nonopsonic phagocytosis by human neutrophils and macrophages. Pediatr Res (1987) 1.62
Quantitation and identification of antibodies to outer-membrane proteins of Pseudomonas aeruginosa in sera of patients with cystic fibrosis. J Infect Dis (1984) 1.62
Burkholderia cepacia genomovar VI, a new member of the Burkholderia cepacia complex isolated from cystic fibrosis patients. Int J Syst Evol Microbiol (2001) 1.61
Conversion of Pseudomonas aeruginosa to the phenotype characteristic of strains from patients with cystic fibrosis. J Clin Microbiol (1990) 1.60
Effect of inoculum size on the susceptibility of Haemophilus influenzae b to beta-lactam antibiotics. Antimicrob Agents Chemother (1979) 1.60
Ampicillin-resistant Hemophilus influenzae in Canada: nationwide survey of hospital laboratories. Can Med Assoc J (1979) 1.59
Opsonophagocytic killing antibody to Pseudomonas aeruginosa mucoid exopolysaccharide in older noncolonized patients with cystic fibrosis. N Engl J Med (1987) 1.59
Burkholderia cepacia complex infection in Italian patients with cystic fibrosis: prevalence, epidemiology, and genomovar status. J Clin Microbiol (2001) 1.50
Fimbriae (pili): molecular basis of Pseudomonas aeruginosa adherence. Clin Invest Med (1986) 1.48
The immediate-early mRNA that encodes the regulatory polypeptide Vmw 175 of herpes simplex virus type 1 is unspliced. EMBO J (1982) 1.47
The benefits of reducing cholesterol levels: the need to distinguish primary from secondary prevention. 1. A meta-analysis of cholesterol-lowering trials. Med J Aust (1991) 1.47
Functional role of mucoid exopolysaccharide (alginate) in antibiotic-induced and polymorphonuclear leukocyte-mediated killing of Pseudomonas aeruginosa. Infect Immun (1991) 1.46
Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes. Drug Metab Dispos (1987) 1.45
Nonopsonic phagocytosis of Pseudomonas aeruginosa by macrophages and polymorphonuclear leukocytes requires the presence of the bacterial flagellum. Infect Immun (1995) 1.45
Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev (2002) 1.43
Patients as a direct source of information on adverse drug reactions. BMJ (1988) 1.42
Systematic review and meta-analysis of the use of fibrin sealant to prevent seroma formation after breast cancer surgery. Br J Surg (2006) 1.41
Recent changes in the profile of prescription NSAID use in Australia. Med J Aust (2000) 1.41
Phagocytosis of unopsonized zymosan by human monocyte-derived macrophages: maturation and inhibition by mannan. J Leukoc Biol (1985) 1.40
Evaluation of a rapid beta-lactamase test for detecting ampicillin-resistant strains of Hemophilus influenzae type b. Pediatrics (1976) 1.39
A tandemly reiterated DNA sequence in the long repeat region of herpes simplex virus type 1 found in close proximity to immediate-early mRNA 1. J Virol (1984) 1.39
Somatostatin in treatment of haematemesis and melaena. Lancet (1985) 1.39
Glucomannan and risk of oesophageal obstruction. Br Med J (Clin Res Ed) (1986) 1.38
DNA sequences which regulate the expression of the pseudorabies virus major immediate early gene. Virology (1987) 1.37
A urinary metabolite ratio that reflects systemic caffeine clearance. Clin Pharmacol Ther (1987) 1.37
Communicability of Pseudomonas aeruginosa in a cystic fibrosis summer camp. J Pediatr (1982) 1.36
Burkholderia cepacia in cystic fibrosis. Variable disease course. Am J Respir Crit Care Med (1999) 1.35
Cholestatic hepatitis associated with flucloxacillin. Med J Aust (1993) 1.34
Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev (2000) 1.33
Oxygen-dependent up-regulation of mucoid exopolysaccharide (alginate) production in Pseudomonas aeruginosa. Infect Immun (1990) 1.32
Role of pulmonary alveolar macrophages in defense of the lung against Pseudomonas aeruginosa. Infect Immun (2000) 1.31
Nonopsonic and opsonic association of Mycobacterium tuberculosis with resident alveolar macrophages is inefficient. J Immunol (1998) 1.29
Serious Pasteurella multocida infections from lion and tiger bites. JAMA (1985) 1.29
Advantage of latex agglutination over countercurrent immunoelectrophoresis in the detection of Haemophilus influenzae type b antigen in serum. Pediatrics (1981) 1.26
The [14C]-aminopyrine breath test. A comparison of different forms of analysis. Br J Clin Pharmacol (1979) 1.26
Molecular epidemiology of Proteus mirabilis infections of the catheterized urinary tract. J Clin Microbiol (2003) 1.25
Prolonged giant cell excretion in severe African measles. Pediatrics (1972) 1.25
Host defenses in patients with cystic fibrosis: modulation by Pseudomonas aeruginosa. Surv Synth Pathol Res (1985) 1.25
Hyponatraemia during carbamazepine treatment. Br Med J (1977) 1.25
In-vitro activity of pefloxacin compared to enoxacin, norfloxacin, gentamicin and new beta-lactams. J Antimicrob Chemother (1985) 1.25
Characterization of lipopolysaccharide-deficient mutants of Pseudomonas aeruginosa derived from serotypes O3, O5, and O6. Infect Immun (1994) 1.24